197 related articles for article (PubMed ID: 4693654)
21. Complement activation in semi-solid medium: Insolubilization of properdin and the third component of complement (C3) in agar gels.
Ziegler JB; Watson L; Goodkofsky I; Alper CA; Lepow IH
J Immunol; 1976 Jan; 116(1):75-9. PubMed ID: 812917
[TBL] [Abstract][Full Text] [Related]
22. Complement activation by heat-killed human kidney cells: formation, activity, and stabilization of cell-bound C3 convertases.
Baker PJ; Adler S; Yang Y; Couser WG
J Immunol; 1984 Aug; 133(2):877-81. PubMed ID: 6376629
[TBL] [Abstract][Full Text] [Related]
23. Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity.
Frémeaux-Bacchi V; Weiss L; Demouchy C; May A; Palomera S; Kazatchkine MD
Nephrol Dial Transplant; 1994; 9(12):1747-50. PubMed ID: 7708258
[TBL] [Abstract][Full Text] [Related]
24. Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.
Schreiber RD; Medicus RG; Gïtze O; Müller-Eberhard HJ
J Exp Med; 1975 Sep; 142(3):760-72. PubMed ID: 1165475
[TBL] [Abstract][Full Text] [Related]
25. [Anticomplement activity of a polyanion: pentosan sulfuric polyester. III. Mechanism of functional inactivation of the different properdin and complement system fractions].
Berthoux FC; Freyria AM; Traeger J
Pathol Biol (Paris); 1977 Mar; 25(3):179-84. PubMed ID: 323787
[TBL] [Abstract][Full Text] [Related]
26. C3 nephritic factor and hypocomplementaemia in a clinically healthy individual.
Gewurz AT; Imherr SM; Strauss S; Gewurz H; Mold C
Clin Exp Immunol; 1983 Oct; 54(1):253-8. PubMed ID: 6616970
[TBL] [Abstract][Full Text] [Related]
27. Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.
Schreiber RD; Götze O; Müller-Eberhard HJ
J Exp Med; 1976 Oct; 144(4):1062-75. PubMed ID: 62010
[TBL] [Abstract][Full Text] [Related]
28. The incorporation of C3 nephritic factor (C3NeF) into a stabilized C3 convertase, C3bBb(C3NeF), and its release after decay of convertase function.
Daha MR; Austen KF; Fearon DT
J Immunol; 1977 Sep; 119(3):812-7. PubMed ID: 894027
[No Abstract] [Full Text] [Related]
29. Complete absence of the third component of complement in man.
Ballow M; Shira JE; Harden L; Yang SY; Day NK
J Clin Invest; 1975 Sep; 56(3):703-10. PubMed ID: 1159084
[TBL] [Abstract][Full Text] [Related]
30. Activation of the alternative pathway of complement in childhood acute lymphoblastic leukemia.
Kalwinsky DK; Urmson JR; Stitzel AE; Spitzer RE
J Lab Clin Med; 1976 Nov; 88(5):745-56. PubMed ID: 1068203
[TBL] [Abstract][Full Text] [Related]
31. Continuing C3 breakdown after bilateral nephrectomy in patients with membrano-proliferative glomerulonephritis.
Vallota EH; Forristal J; Spitzer RE; Davis NC; West CD
J Clin Invest; 1971 Mar; 50(3):552-8. PubMed ID: 5101779
[TBL] [Abstract][Full Text] [Related]
32. Functional relationship of factor B in the properdin system to C3 proactivator of human serum.
Goodkofsky I; Lepow IH
J Immunol; 1971 Oct; 107(4):1200-4. PubMed ID: 5093780
[No Abstract] [Full Text] [Related]
33. Human glomerulonephritis and the C3 nephritic factor (C3NeF).
Berthoux FC; Carpenter CB; Freyria AM; Traeger J; Merrill JP
Clin Nephrol; 1976 Mar; 5(3):93-100. PubMed ID: 57022
[No Abstract] [Full Text] [Related]
34. Breakdown products of C3 and factor B in hemolytic-uremic syndrome.
Kim Y; Miller K; Michael AF
J Lab Clin Med; 1977 Apr; 89(4):845-50. PubMed ID: 845484
[TBL] [Abstract][Full Text] [Related]
35. Alternative pathway of complement: nonenzymatic, reversible transition of precursor to active properdin.
Götze O; Medicus RG; Müller-Eberhard HJ
J Immunol; 1977 Feb; 118(2):525-32. PubMed ID: 839069
[TBL] [Abstract][Full Text] [Related]
36. Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection.
Alper CA; Abramson N; Johnston RB; Jandl JH; Rosen FS
J Clin Invest; 1970 Nov; 49(11):1975-85. PubMed ID: 4097977
[TBL] [Abstract][Full Text] [Related]
37. Systemic lupus erythematosus, partial lipodystrophy and hypocomplementemia.
Jasin HE
J Rheumatol; 1979; 6(1):43-50. PubMed ID: 439110
[TBL] [Abstract][Full Text] [Related]
38. The rabbit properdin system: I. Identification of a new factor and purification of rabbit properdin.
Naff GB; Hedrick SW; Ratnoff WD; Novak MA; Smith MC; Steiner C; Todd EW
J Immunol; 1980 Jun; 124(6):2625-31. PubMed ID: 6900053
[TBL] [Abstract][Full Text] [Related]
39. Properdin anc C3 proactivator: alternate pathway components in human glomerulonephritis.
McLean RH; Michael AF
J Clin Invest; 1973 Mar; 52(3):634-44. PubMed ID: 4630981
[TBL] [Abstract][Full Text] [Related]
40. A properdin system intermediate formed by zymosan and serum at 0 degrees C.
Yukiyama Y; Lew FT; Waks HS; Osler AG
J Immunol; 1976 Jan; 116(1):188-93. PubMed ID: 812914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
